Genome Editing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Techniques (CRISPR-Cas9, TALENs, ZFNs, Homing Endonucleases, PASTE, Prime Editing Systems, and Others), By Application (Engineering Cell Lines and Organisms, Synthetic Biology and Genome-Scale Engineering, Therapeutic Genome Editing, Diagnostics, Drug Discovery and Development, and Others), By End Users (Biotechnology and Pharmaceutical Companies, Academic and Research Organizations, Contract Research Organizations, and Others) and Region Forecast 2019 - 2030

Genome Editing Market size was valued at US$ 5,648.3 million in 2023 and is expected to grow at a CAGR of 12.8% from 2024-2030. The market is a fast-growing sector within the field of Biotechnology, offering revolutionary tools and techniques for editing the genetic makeup of the living organism to address various challenges in healthcare, agriculture, and other industries. According to the National Human Genome Research Institute, around 350 million people on earth have a rare disorder, which has been identified in fewer than 200,000 people. About 80% of these uncommon ailments are genetically based, and 95% don't even have one FDA-approved medication. This rising prevalence of rare genetic disorders, congenital disorders, and chronic diseases is driving the market.

Moreover, Advancements in genome editing techniques coupled with rising demand for personalized medicine and targeted therapies are accelerating the market further. However, ethical and regulatory concerns, off-target effects and safety concerns, delivery challenges, and high development and implementation costs are some of the factors that restrain the growth of the market. Furthermore, the market is witnessing several key trends including the development of novel genome editing tools, advancements in genome editing tool delivery systems, and the rise of therapeutic application.

The growing interest and investment in genome editing research contribute to market growth and several companies are participating in launching new tools and techniques. In May 2023, Mission Bio introduced a new end-to-end product, Tapestri Genome Editing Solution, for the analysis of genome editing. In March 2021, Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, launched its rhAmpSeq CRISPR Analysis System, which offers an end-to-end solution for characterizing and quantifying the full array of on- and off-target genome editing events in CRISPR research projects.

Key Developments

• In May 2023, Pairwise, a health-focused food and agriculture company launched the Fulcrum Platform, which is built on proprietary CRISPR technology along with other custom gene editing tools
• In September 2022, global genomics solutions provider, Integrated DNA Technologies (IDT) has expanded access to its customization options for the Alt-R Custom CRISPR gRNA Libraries.